Madison Investment Advisors LLC Acquires Shares of 46,904 Genmab A/S (NASDAQ:GMAB)

Madison Investment Advisors LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 46,904 shares of the company's stock, valued at approximately $979,000.

A number of other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Genmab A/S by 27.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 22,204 shares of the company's stock valued at $463,000 after purchasing an additional 4,835 shares during the last quarter. Callan Family Office LLC bought a new stake in shares of Genmab A/S in the 4th quarter valued at $225,000. Lindbrook Capital LLC boosted its holdings in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Genmab A/S during the fourth quarter valued at about $2,463,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GMAB. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Truist Financial reduced their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Finally, Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and an average price target of $41.33.

Remove Ads

Genmab A/S Stock Up 2.9 %

GMAB stock traded up $0.56 during trading on Wednesday, reaching $19.62. The company's stock had a trading volume of 1,315,653 shares, compared to its average volume of 922,360. The company's fifty day moving average is $20.94 and its 200-day moving average is $22.00. The company has a market capitalization of $12.98 billion, a P/E ratio of 11.28, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.02.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.